Clinical utilization of the international normalized ratio (INR)

Journal of Clinical Laboratory Analysis

Volumn 14, Issue 3, 2000, Pages 101-114

  Riley, Roger S ^a   Rowe, David ^a   Fisher, Lyman M ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

International Normalized Ratio; Oral anticoagulants; Prothrombin time; Thromboembolic disease

Indexed keywords

ANTICOAGULANT AGENT; THROMBOPLASTIN; WARFARIN;

ANTICOAGULANT THERAPY; ARTICLE; BLOOD CLOTTING; DRUG MONITORING; HUMAN; INTERNATIONAL STANDARD UNIT; PATIENT MONITORING; PROTHROMBIN TIME; QUALITY CONTROL; STANDARDIZATION; THROMBOEMBOLISM; WORLD HEALTH ORGANIZATION;

HEMATOLOGY; HUMANS; INTERNATIONAL NORMALIZED RATIO; PROTHROMBIN TIME;

ORYCTOLAGUS CUNICULUS;

EID: 0034062823     PISSN: 08878013     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2825(2000)14:3<101::AID-JCLA4>3.0.CO;2-A     Document Type: Article

References (162)

1. Fairweather RB, Ansell J, van den Besselaar AMHP, et al. College of American Pathologist Conference XXXI on Laboratory Monitoring of Anticoagulant therapy. Laboratory monitoring of oral anticoagulant therapy. Arch Pathol Lab Med 1998;122:768-781.
2. Majerus PW, Broze GJ Jr., Miletich JP, Tollefsen DM. Anticoagulant, thrombolytic, and antiplatelet drugs. In: Hardman JG et al., editors. Goodman and Gilman's The pharmacological basis of therapeutics. New York: McGraw-Hill;1996. p. 1346-1350.
3. Hirsh J, Dalen JE, Deykin D, Poller L. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 1992;102(Suppl.): 312S-326S,
4. Arky R. Physicians' desk reference. Montvale, NJ: Medical Economics Company, Inc.; 1999. p. 929-933.
5. Yacobi A, Udall JA, Levy G. Serum protein binding as a determinant of warfarin body clearance and anticoagulant effect. Clin Pharmacol Ther 1976;19:552-558.
6. Katsuki T, Saito M, Noda T, Yaginuma T, Hosoda S. Long-term follow-up in patients receiving anticoagulation therapy: potency of therapy and complications. J Cardiol 1994;24:203-209.
7. Horton JD, Bushwick BM. Warfarin therapy: evolving strategies in anticoagulation. Am Fam Physician 1999;59:635-646.
8. Hirsh J, Poller L, Deykin D, Levine M, Dalen JE. Optimal therapeutic range for oral anticoagulants. Chest 1989;95(Suppl. 2):5S-10S.
9. Van den Besselaar A, Evatt B, et al. Proficiency testing and standardization of prothrombin time: effect of thromboplastin, instrumentation, and plasma. Am J Clin Pathol 1984;82:688-689.
10. Bradlow BA. Prothrombin time: standardizing and controlling anticoagulant therapy. ASCP Check Sample PTS 1992;92-8 8:1-7.
11. Jordan CD, Flood JG, Laposata M, Lewandrowski KB. Normal reference laboratory values. N Engl J Med 1992;327:718-724.
12. Vanscoy GJ, Krause JRS. Warfarin and the International Normalized Ratio: reducing interlaboratory effect. Ann Pharmacother 1991; 25:1190-1192.
13. van den Besselaar AM. The response of Quick's prothrombin time test to oral anticoagulation. Influence of thromboplastin source and calcium chloride concentration. Arch Pathol Lab Med 1994;118:145-149.
14. Standards NCfCL. One-stage prothrombin time test (PT) - tentative guideline. In NCCLS document H28-T. Villanova, PA: National Committee for Clinical Laboratory Standards; 1992.
15. Standards NCfCL. Collection, transport, and preparation of blood specimens for coagulation testing and performance of coagulation assays. In NCCLS document H21-A2. Villanova, PA: National Committee for Clinical Laboratory Standards; 1991.
16. Kolde HJ, Ramirez I. Experience with a thromboplastin based on recombinant tissue factor and synthetic phospholipids. Hamostaseologie 1994; 14:90-99.
17. Lindley CM, Sawyer WT, Macik BG, et al. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther 1994;55:638-648.
18. Solomon HM, Randall JR, Simmons VL. Heparin-induced increase in the international normalized ratio. Responses of 10 commercial thromboplastin reagents. Am J Clin Pathol 1995;103:735-739.
19. WHO Expert Committee on Biological Standardization. WHO, 28th Report: WHO technical report series 610. Geneva, Switzerland; 1977. p. 14-14, 45-51.
20. Kirkwood TBL. Calibration of reference thromboplastins and standardization of the prothrombin time ratio. Thromb Haetnost 1983;49:238-244.
21. Loeliger EA. ICSH/ICTH recommendations for reporting prothrombin time in oral anticoagulant control. Thromb Haemost 1985;49:238-244.
22. Poller L. Progress in standardization in anticoagulant control. Hematol Rev 1987;1:225-241.
23. Taberner DA, Poller L, Thomson JM, Darby KV. Effect of internal sensitivity index (ISI) of thromboplastins on precision of international normalised ratios (INR). J Clin Pathol 1989;42:92-96.
24. Brophy MT, Fiore LD, Lau J, et al. Comparison of a standard and a sensitive thromboplastin in monitoring low intensity oral anticoagulant therapy. Am J Clin Pathol 1994;102:134-137.
25. Vondergeest JS. How does a low ISI increase the benefit of the INR reporting system? Clin Hemostasis Rev 1993;7.
26. Pathologists Co A. Coagulation (comprehensive) survey set CG2-C participant survey. 1999.
27. Ng VL, Valdes-Camin R, Gottfried EL, et al. Highly sensitive thromboplastins do not improve INR precision. Am J Clin Pathol 1998;109:338-346.
28. Poller L, Van Den Besselaar AM, Jespersen J, Tripodi A, Houghton D. The effect of sample size on fresh plasma thromboplastin ISI determination. Br J Haematol 1999;105:655-663.
29. Poller L, Hirsh J. Special report: a simple system for the derivation of international normalized ratios for the reporting of prothrombin time results with North American thromboplastin reagents. Am J Clin Pathol 1989;92:124-126.
30. Dalere GM, Coleman RW, Lum BL. A graphic nomogram for warfarin dosage adjustment. Pharmacotherapy 1999;19:461-467.
31. Kumar S, Haigh JR, Rhodes LE, et al. Poor compliance is a major factor in unstable outpatient control of anticoagulant therapy. Thromb Haemost 1989;62:729-732.
32. Arnsten JH, Gelfand JM, Singer DE. Determinants of compliance with anticoagulation: a case-control study. Am J Med 1997;103:11-17.
33. Brigden ML. Oral anticoagulant therapy: practical aspects of management. Postgrad Med 1996;99:81-84, 87-89, 93-94.
34. Standards NCfCL. Collection, transport, and preparation of blood specimens for coagulation testing and performance of coagulation assays; approved guideline, 3rd edition. NCCLS document H21-A3 18. Villanova, PA: National Committee for Clinical Laboratory Standards; 1998.
35. Dwyre AL, Giles AR, Key LA, et al. The effects of sodium citrate anticoagulant concentration, storage on or off cellular matrix, and specimen age on prothrombin time INR using a low ISI (1.06) rabbit brain thromboplastin. Thromb Haemost 1995;73:1237(Abstract 129).
36. Chantarangkul V, Tripodi A, Clerici M, Negri B, Mannucci PM. Assessment of the influence of citrate concentration on the International Normalized Ratio (INR) determined with twelve reagent-instrument combinations. Thromb Haemost 1998;80:258-262.
37. Adcock DM, Kressin DC, Marlar RA. Effect of 3.2% vs. 3.8% sodium citrate concentration on routine coagulation testing. Am J Clin Pathol 1997;107:105-110.
38. Hirsh J, Poller L. The international normalized ratio: a guide to understanding and correcting its problems. Arch Intern Med 1994;154:282-288.
39. Swaim WR. Prothrombin time reporting and the International Normalized Ratio system. Improvements are needed. Am J Clin Pathol 1993;99:653-655.
40. Finazzi G, Falanga A, Galli M, et al. Recombinant versus high-sensitivity conventional thromboplastin: a randomized clinical study in patients on oral anticoagulation. Thromb Haemost 1994;72:804-807.
41. Baele G, Fiers T, Leroux-Roels G. Comparison of a recombinant thromboplastin with Thrombotest for oral anticoagulant control. Haemostasis 1996;26:11-15.
42. Seyfert U, Sorg L, Wenzel E, Denzler B, Kolde HJ. The determination of the prothrombin time in capillary blood using a thromboplastin based on recombinant tissue factor and synthetic phospholipids. Klin Labor 1994;40:7-8.
43. Kitchen S, Jennings I, Woods TA, Walker ID, Preston FE. Two recombinant tissue factor reagents compared to conventional thromboplastins for determination of international normalised ratio: a thirty-three-laboratory collaborative study. The Steering Committee of the UK National External Quality Assessment Scheme for Blood Coagulation. Thromb Haemost 1996;76:372-376.
44. D'Angelo A, Seveso MP, D'Angelo SV, et al. Comparison of two automated coagulometers and the manual tilt-tube method for the determination of prothrombin time. Am J Clin Pathol 1989;92:321-328.
45. Poggio M. The effect of instruments for prothrombin time testing on the international normalized ratio. Ric Clin Lab 1990;20:71-74.
46. Inciardi JF. Assessing random error in the international normalized ratio. Ther Drug Monit 1994;16:425-426.
47. Ford K, McArdle B, Kesteven PJ. A comparison of five commercial thromboplastins: ISI re-evaluation on an automated coagulometer. Clin Lab Haematol 1995;17:41-45.
48. Pi DW, Raboud JM, Filby C, Carter CJ. Effect of thromboplastin and coagulometer interaction on the precision of the International Normalised Ratio. J Clin Pathol 1995;48:13-17.
49. Lind SE, Pearce LA, Feinberg WM, Bovill EG. Clinically significant differences in the International Normalized Ratio measured with reagents of different sensitivities. SPAF Investigators. Stroke Prevention in Atrial Fibrillation. Blood Coagul Fibrinolysis 1999;10:215-227.
50. van den Besselaar AM, Houbouyan LL, Aillaud MF, et al. Influence of three types of automated coagulometers on the International Sensitivity Index (ISI) of rabbit, human, and recombinant human tissue factor preparations. Thromb Haemost 1999;81:66-70.
51. Critchfield GC, Bennett ST, Swaim WR. Calibration verification of the International Normalized Ratio. Am J Clin Pathol 1996;106:786-794.
52. Kitchen S, Jennings I, Woods TA, Preston FE. Local calibration of international normalised ratio improves between laboratory agreement: results from the UK National External Quality Assessment Scheme. Thromb Haemost 1999;81:60-65.
53. Kitchen S, Preston FE. Standardization of prothrombin time for laboratory control of oral anticoagulant therapy. Semin Thromb Hemost 1999;25:17-25.
54. Dufty JM, Craig S, Stevenson KJ, Taberner DA. Calculation of System International Sensitivity Index: how many calibrant plasmas are required? J Clin Pathol 1997;50:40-44.
55. Poller L, Barrowcliffe TW, van den Besselaar AM, et al. Minimum lyophilized plasma requirement for ISI calibration. Am J Clin Pathol 1998;109:196-204,
56. Poller L, Thomson JM, Taberner DA, Clarke DK. The correction of coagulometer effects on international normalized ratios: a multicentre evaluation. Br J Haematol 1994;86:112-117.
57. Hubbard AR, Margetts SM, Barrowcliffe TW. International Normalized Ratio determination using calibrated reference plasmas. Br J Haematol 1997;98:74-78.
58. Poller L, van den Besselaar AM, Jespersen J, Tripodi A, Houghton D. A comparison of linear and orthogonal regression analysis for local INR determination in ECAA coagulometer studies. Br J Haematol 1998;102:910-917.
59. Johnston M, Brigden M. A cross-Canada survey of prothrombin time testing: does the establishment of local ISI values improve the accuracy of international normalized ratio reporting? Am J Clin Pathol 1998;110:683-690.
60. Poller L. Screening INR deviation of local prothrombin time systems. J Clin Pathol 1998;51:356-359.
61. Houbouyan LL, Goguel AF. Long-term French experience in INR standardization by a procedure using plasma calibrants. Am J Clin Pathol 1997;108:83-89.
62. Brien WF, Baskerville JC, Taberner DA, Crawford L. Calculation vs calibration curve for INR determination. Results of an interlaboratory proficiency scheme. Am J Clin Pathol 1999;111:193-201.
63. Triplett DA, Brandt J. International normalized ratios. Has their time come? Arch Pathol Lab Med 1993;117:590-592.
64. Critchfield GC, Bennett ST. The influence of the reference mean prothrombin time in the International Normalized Ratio. Am J Clin Pathol 1994;102:806-811.
65. van den Besselaar AM, Meeuwisse-Braun J, Schaefer-van Mansfeld H, Witteveen E, van Rijn C. Influence of plasma volumetric errors on the prothrombin time ratio and International Sensitivity Index. Blood Coagul Fibrinolysis 1997;8:431-435.
66. Douketis JD, Lane A, Milne J, Ginsberg JS. Accuracy of a portable International Normalization Ratio monitor in outpatients receiving long-term oral anticoagulant therapy: comparison with a laboratory reference standard using clinically relevant criteria for agreement. Thromb Res 1998;92:11-17.
67. Hasenkam JM, Kimose HH, Knudsen L, et al. Self management of oral anticoagulant therapy after heart valve replacement. Eur J Cardiothorac Surg 1997;11:935-942.
68. Hasenkam JM, Knudsen L, Kimose HH, et al. Practicability of patient self-testing of oral anticoagulant therapy by the international normalized ratio (INR) using a portable whole blood monitor. A pilot investigation. Thromb Res 1997;85:77-82.
69. Tschaikowsky K, Balint R, Pscheidl E, Bremer F. Prothrombin time and thromboplastin time. On-site measurement of the prothrombin time and activated partial thromboplastin time of surgical patients with laser photometry. Anaesthesist 1998;47:295-302.
70. van den Besselaar AM, Breddin K, Lutze G, et al. Multicenter evaluation of a new capillary blood prothrombin time monitoring system. Blood Coagul Fibrinolysis 1995;6:726-732.
71. Chapman DC, Stephens MA, Hamann GL, Bailey LE, Dorko CS. Accuracy, clinical correlation, and patient acceptance of two handheld prothrombin time monitoring devices in the ambulatory setting. Ann Pharmacother 1999;33:775-780.
72. Massicotte P, Marzinotto V, Vegh P, Adams M, Andrew M. Home monitoring of warfarin therapy in children with a whole blood prothrombin time monitor. J Pediatr 1995;127:389-394.
73. Kitchen S, Preston FE. Monitoring oral anticoagulant treatment with the TAS near-patient test system: comparison with conventional thromboplastins. J Clin Pathol 1997;50:951-956.
74. Tripodi A, Chantarangkul V, Clerici M, Negri B, Mannucci PM. Determination of the International Sensitivity Index of a new near-patient testing device to monitor oral anticoagulant therapy - overview of the assessment of conformity to the calibration model. Thromb Haemost 1997;78:855-858.
75. Cachia PG, McGregor E, Adlakha S, Davey P, Goudie BM. Accuracy and precision of the TAS analyser for near-patient INR testing by nonpathology staff in the community. J Clin Pathol 1998;51:68-72.
76. Check W. The INR gaining recognition. CAP Today 1993;7:1-26.
77. Yim JM, Albers GW, Vlasses PH. Anticoagulant therapy monitoring with international normalized ratio at US academic health centers. Ann Pharmacother 1996;30:1390-1395.
78. Albers GW. Laboratory monitoring of oral coagulant therapy: are we being misled? Neurology 1993;43:468-470.
79. Hirsh J. Substandard monitoring of warfarin in North America: time for change. Arch Intern Med 1992;152:257-258.
80. Hirsh J. Optimal intensity and monitoring warfarin. Am J Cardiol 1995;75:39B-42B.
81. Litin SC, Gastineau DA. Current concepts in anticoagulant therapy. Mayo Clin Proc 1995;70:266-272.
82. Cannegieter SC, Torn M, Rosendaal FR. Oral anticoagulant treatment in patients with mechanical heart valves: how to reduce the risk of thromboembolic and bleeding complications. J Intern Med 1999; 245:369-374.
83. Sachdev GP, Ohlrogge KD, Johnson CL. Review of the Fifth American College of Chest Physicians Consensus Conference on Antithrombotic Therapy: outpatient management for adults. Am J Health Syst Pharm 1999;56:1505-1514.
84. Ts'ao C, Neofotistos D. The use and limitations of the INR system. Am J Hematol 1994;47:21-26.
85. Loeliger EA, Poller L, Samama M, et al. Questions and answers on prothrombin time standardization in oral anticoagulant therapy. Thromb Haemost 1985;54:515-17.
86. Ponte CD. Practical dosing considerations for warfarin therapy. Drug Information Bulletin (WVU School of Pharmacy) 1992;17:21-22.
87. Harrison L, Johnston M, Massicotte MP, et al. Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med 1997;126:133-136.
88. Crowther MA, Ginsberg JB, Kearon C, et al. A randomized trial comparing 5-mg and 10-mg warfarin loading doses. Arch Intern Med 1999;159:46-48.
89. Oates A, Jackson PR, Austin CA, Channer KS. A new regimen for starting warfarin therapy in out-patients. Br J Clin Pharmacol 1998;46:157-161.
90. Blann A, Hewitt J, Siddiqui F, Bareford D. Racial background is a determinant of average warfarin dose required to maintain the INR between 2.0 and 3.0. Br J Haematol 1999;107:207-209.
91. Ginsberg J, Hirsh J. Use of anticoagulants during pregnancy. Chest 1989;95(Suppl. 2S):156S-160S.
92. Wong V, Cheng CH, Chan KC. Fetal and neonatal outcome of exposure to anticoagulants during pregnancy. Am J Med Genet 1993;45:17-21.
93. Myers KE, Nakamura JM. Maternal and fetal sequelae of anticoagulation during pregnancy. Am J Cardiol 1990;65:1410.
94. Bates SM, Ginsberg JS. Anticoagulants in pregnancy: fetal effects. Baillieres Clin Obstet Gynaecol 1997;11:479-488.
95. Barbour LA. Current concepts of anticoagulant therapy in pregnancy. Obstet Gynecol Clin North Am 1997;24:499-521.
96. Ginsberg JS, Hirsh J. Use of antithrombotic agents during pregnancy. Chest 1998;114:524S-530S.
97. Wehrmacher WH, Karlman RL, Scanlon P, Messmore HL, Jr. Anticoagulant therapy of thromboembolic disease during pregnancy. Compr Ther 1998;24:289-294.
98. Streif W, Andrew M, Marzmotto V, et al. Analysis of warfarin therapy in pediatric patients: a prospective cohort study of 319 patients. Blood 1999;94:3007-3014.
99. Bleske BE, Welage LS, Warren EW, Brown MB, Shea MJ. Variations in prothrombin time and international normalized ratio over 24 hours in warfarin-treated patients. Pharmacotherapy 1995;15: 709-712.
100. Sun J, Chang MW. Initialization of warfarin dosages using computer modeling. Arch Phys Med Rehabil 1995;76:453-456.
101. White RH, McKittrick T, Hutchinson R, Twitchell J. Temporary discontinuation of warfarin therapy: changes in the international normalized ratio. Ann Intern Med 1995;122:40-42.
102. Palareti G, Legnani C, Guazzaloca G, et al. Activation of blood coagulation after abrupt or stepwise withdrawal of oral anticoagulants: a prospective study. Thromb Haemost 1994;72:222-226.
103. Genewein U, Haeberli A, Straub PW. Beer JH. Rebound after cessation of oral anticoagulant therapy: the biochemical evidence. Br J Haematol 1996;92:479-485.
104. Carrel TP, Klingenmann W, Mohacsi PJ, Berdat P, Althaus U. Perioperative bleeding and thromboembolic risk during non-cardiac surgery in patients with mechanical prosthetic heart valves: an institutional review. J Heart Valve Dis 1999;8:392-398.
105. Lousberg TR, Witt DM, Beall DG, Carter BL, Malone DC. Evaluation of excessive anticoagulation in a group model health maintenance organization. Arch Intern Med 1998;158:528-534.
106. Wentzien TH, O'Reilly RA, Kearns PJ. Prospective evaluation of anticoagulant reversal with oral vitamin K1 while continuing warfarin therapy unchanged. Chest 1998;114:1546-1550.
107. Makris M, Greaves M, Phillips WS, et al. Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Haemost 1997;77:477-480.
108. Hylek EM, Heiman H, Skates SJ, Sheehan MA, Singer DE. Acetaminophen and other risk factors for excessive warfarin anticoagulation. JAMA 1998;279:657-662.
109. Murphy PT, Casey MC, Abrams K. Audit of patients on oral anticoagulants with International normalized ratios of eight or above. Clin Lab Haematol 1998;20:253-257.
110. Levine M, Raskob G, Hirsh J. Hemorrhagic complications of long-term anticoagulant therapy. Chest 1989;95(Suppl. 2S):26S-36S.
111. Pineo GF, Hull RD. Adverse effects of coumarin anticoagulants. Drug Saf 1993;9:263-271.
112. Caliendo FJ, Halpern VJ, Marini CP, et al. Warfarin anticoagulation in the perioperative period: is it safe? Ann Vasc Surg 1999;13:11-16.
113. Schenk JF, Morsdorf S, Pindur G, et al. Analysis and occurrence of adverse events with oral anticoagulant therapy. Semin Thromb Hemost 1999;25:65-71.
114. Gorter JW. Major bleeding during anticoagulation after cerebral ischemia: patterns and risk factors. Stroke Prevention In Reversible IschemiaTrial (SPIRIT). European Atrial Fibrillation Trial (EAFT) study groups. Neurology 1999;53:1319-1327.
115. Gullov AL, Koefoed BG, Petersen P. Bleeding during warfarin and aspirin therapy in patients with atrial fibrillation: the AFASAK 2 study. Arch Intern Med 1999;159:1322-1328.
116. Hyman BT, Landas SK, Ashman RF, Schelper RL, Robinson RA. Warfarin-related purple toes syndrome and cholesterol microembolization. Am J Med 1987;82:1233-1237.
117. Zaman S, Mallya J, Thomas M. A man with purple toes. Postgrad Med J 1998;74:51-55.
118. Sternberg ML, Pettyjohn FS. Warfarin sodium-induced skin necrosis. Ann Emerg Med 1995;26:94-97.
119. Sallah S, Thomas DP, Roberts HR. Warfarin and heparin-induced skin necrosis and the purple toe syndrome: infrequent complications of anticoagulant treatment. Thromb Haemost 1997;78:785-790.
120. Wynn SS, Jin DK, Essex DW. Warfarin-induced skin necrosis occurring four days after discontinuation of warfarin. Haemostasis 1997;27:246-250.
121. Essex DW, Wynn SS, Jin DK. Late-onset warfarin-induced skin necrosis: case report and review of the literature. Am J Hematol 1998;57:233-237.
122. Makris M, Bardhan G, Preston FE. Warfarin induced skin necrosis associated with activated protein C resistance. Thromb Haemost 1996;75:523-524.
123. Yang Y, Algazy KM. Warfarin-induced skin necrosis in a patient with a mutation of the prothrombin gene. N Engl J Med 1999;340:735.
124. Lewandowski K, Zawilska K. Protein C concentrate in the treatment of warfarin-induced skin necrosis in the protein C deficiency. Thromb Haemost 1994;71:395.
125. Schramm W, Spannagl M, Bauer KA, et al. Treatment of coumarin-induced skin necrosis with a monoclonal antibody purified protein C concentrate. Arch Dermatol 1993;129:753-756.
126. Knowlton CH, Thomas OV, Williamson A, et al. Establishing community pharmacy-based anticoagulation education and monitoring programs. J Am Pharm Assoc (Wash) 1999;39:368-374.
127. Kulinna W, Key D, Wenzel T, Heene DL, Harenberg J. The effect of self-monitoring the INR on quality of anticoagulation and quality of life. Semin Thromb Hemost 1999;25:123-126.
128. Li Q, Tosiello L. Patient self-management of oral anticoagulation. JAMA 1999;281:2283-2284.
129. Sawicki PT. A structured teaching and self-management program for patients receiving oral anticoagulation: a randomized controlled trial. JAMA 1999;281:145-150.
130. Sorano GG, Biondi G, Conti M, et al. Controlled vitamin K content diet for improving the management of poorly controlled anticoagulated patients: a clinical practice proposal. Haemostasis 1993;23:77-82.
131. Taylor JR ,Wilt VM. Probable antagonism of warfarin by green tea. Ann Pharmacother 1999;33:426-428.
132. Cohen H, Scott SD, Mackie IJ, et al. The development of hypoprothrombinaemia following antibiotic therapy in malnourished patients with low serum vitamin K1 levels. Br J Haematol 1988;68:63-66.
133. Crowther MA, Donovan D, Harrison L, McGinnis J, Ginsberg J. Low-dose oral vitamin K reliably reverses over-anticoagulation due to warfarin. Thromb Haemost 1998;79:1116-1118.
134. Hirsh J. Reversal of the anticoagulant effects of warfarin by vitamin K1. Chest 1998;114:1505-1508.
135. Whitling AM, Bussey HI, Lyons RM. Comparing different routes and doses of phytonadione for reversing excessive anticoagulation. Arch Intern Med 1998;158:2136-2140.
136. Nee R, Doppenschmidt D, Donovan DJ, Andrews TC. Intravenous versus subcutaneous vitamin K1 in reversing excessive oral anticoagulation. Am J Cardiol 1999;83:286-288,A6-7.
137. Brigden ML. When bleeding complicates oral anticoagulant therapy. How to anticipate, investigate, and treat. Postgrad Med 1995;98:153-154,159-162,164-165.
138. Chu K, Wu SM, Stanley T, Stafford DW, High KA. A mutation in the propeptide of Factor IX leads to warfarin sensitivity by a novel mechanism. J Clin Invest 1996;98:1619-1625.
139. Oldenburg J, Quenzel EM, Harbrecht U, et al. Missense mutations at ALA-10 in the factor IX propeptide: an insignificant variant in normal life but a decisive cause of bleeding during oral anticoagulant therapy. Br J Haematol 1997;98:240-244.
140. Peters J, Luddington R, Brown K, Baglin C, Baglin T. Should patients starting oral anticoagulant therapy be screened for missense mutations at Ala-10 in the factor IX propeptide? Br J Haematol 1997;99:467-468.
141. van der Meer FJM, Vos HL, Rosendaal FR. No indication for APTT screening in patients on oral anticoagulant therapy. Thromb Haemost 1999;81:364-366.
142. Lubetsky A, Dekel-Stern E, Chetrit A, Halkin H. Vitamin k intake and sensitivity to warfarin in patients consuming regular diets. Thromb Haemost 1999;81:396-399.
143. Bentley DP, Backhouse G, Hutchings A, et al. Investigation of patients with abnormal response to warfarin. Br J Clin Pharmacol 1986;22:37-41.
144. Weibert RT, Le DT, Kayser SR, Rapaport SI. Correction of excessive anticoagulation with low-dose oral vitamin K1. Ann Intern Med 1997;126:959-962.
145. Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999;353:717-719.
146. Mannucci PM. Genetic control of anticoagulation. Lancet 1999; 353:688-689.
147. Tasken RAR, Nakatsu K. Rapid, reliable and sensitivity assay for warfarin using normal phase high performance liquid chromatography. J Chromatogr 1982;228:346-349.
148. Cannon DJ, Wolfson WL. Therapeutic drug monitoring and toxicity. In: Jacobs DS et al., editors. Laboratory test handbook. Baltimore: Williams and Wilkins; 1990. p. 826-827.
149. Riley RS, Friedline J, Rogers JS. Antiphospholipid antibodies: standardization and testing. Clin Lab Med 1997; 17:395-430.
150. Espinoza LR. Antiphospholipid antibody syndrome: treatment. Lupus 1996;5:456-457.
151. Prandoni P, Simioni P, Girolami A. Antiphospholipid antibodies, recurrent thromboembolism, and intensity of warfarin anticoagulation. Thromb Haemost 1996;75:859.
152. Elezovic I, Miljic P, Antunovic P, et al. The management of antiphospholipid syndrome. Vojnosanit Pregl 1998;55:41-46.
153. Piette JC, Piette AM. Management of the antiphospholipid syndrome. Main trends, unsolved questions, practical and educational aspects. Ann Med Interne (Paris) 1996;147(Suppl)1:28-31.
154. Douketis JD, Crowther MA, Julian JA, et al. The effects of low-intensity warfarin on coagulation activation in patients with antiphospholipid antibodies and systemic lupus erythematosus. Thromb Haemost 1999;82:1028-1032.
155. Khamashta MA, Cuadrado MJ, Mujic F, et al. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995;332:993-997.
156. Wisbey HL, Klestov AC. Thrombocytopenia corrected by warfarin in antiphospholipid syndrome. J Rheumatol 1996;23:769-771.
157. Arnout J, Vermylen J. Lupus anticoagulant: influence on the international normalized ratio. Thromb Haemost 1999;81:847-849.
158. Della Valle P, Crippa L, Safa O, et al. Potential failure of the International Normalized Ratio (INR) System in the monitoring of oral anticoagulation in patients with lupus anticoagulants. Ann Med Interne (Paris) 1996;147(Suppl)1:10-14.
159. Lawrie AS, Purdy G, Mackie IJ, Machin SJ. Monitoring of oral anticoagulant therapy in lupus anticoagulant positive patients with the antiphospholipid syndrome. Br J Haematol 1997;98:887-892.
160. Moll S, Ortel TL. Monitoring warfarin therapy in patients with lupus anticoagulants. Ann Intern Med 1997;127:177-185.
161. Robert A, Le Querrec A, Delahousse B, et al. Control of oral anticoagulation in patients with the antiphospholipid syndrome - influence of the lupus anticoagulant on International Normalized Ratio. Thromb Haemost 1998;80:99-103.
162. Leech BF, Carter CJ. Falsely elevated INR results due to the sensitivity of a thromboplastin reagent to heparin. Am J Clin Pathol 1998;109:764-768.